What’s Next For CVS Health Stock After Q3 Beat?

+30.10%
Upside
67.77
Market
88.17
Trefis
CVS: CVS Health logo
CVS
CVS Health

[Updated: Nov 8, 2021] CVS Stock Rise

The stock price of CVS Health (NYSE: CVS) has seen a rise of 11% over the last month, while it is up 7% over the last ten days. The recent rise can be attributed to its upbeat Q3 results. The company’s Q3 revenue of $73.8 billion was up 10% y-o-y and comfortably above our estimate of $70.6 billion. The revenue growth was driven by increased prescription volume and from Covid-19 vaccination and testing administration. CVS’ bottom line of $1.97 on a per share and adjusted basis was up 19% y-o-y, and well above our estimate of $1.81. Following a solid Q3, CVS revised its full-year 2021 outlook upward with revenue now estimated to be around $288 billion and EPS to be $7.95, at mid-point of their range. This compares with the company’s prior guidance of $283 billion and $7.75, respectively. This has boded well with the investors, evident from the nearly 6% rise in CVS stock in a single trading session on Nov 3, following its earnings announcement.

But now that CVS stock has seen a rise of 11% over the last month or so, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a higher chance of a rise in CVS stock over the next month. Out of 120 instances in the last ten years that CVS stock saw a twenty-one day rise of 11% or more, 64 of them resulted in CVS stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 64 out of 120, or about a 53% chance of a rise in CVS stock over the coming month. See our analysis on CVS Health Stock Chance of Rise for more details. That said, 53% chance is surely not a great figure to bet on. Furthermore, going by our updated CVS Health Valuation of $99 per share, based on $8.00 expected adjusted EPS and maintaining a 12x P/E multiple for 2021, there is only 5% upside for CVS stock from its current level of around $94. As such, we believe that it may be prudent to wait for a correction to enter into CVS stock for better gains.

Relevant Articles
  1. Should You Pick CVS Stock At $75 After A 6% Fall This Year?
  2. Is CVS Health Stock Undervalued At $70?
  3. Will CVS Health Stock Recover To Its Pre-Inflation Shock Highs of $110?
  4. Higher Costs To Weigh On CVS Health’s Q2?
  5. Should You Buy CVS Stock At $70?
  6. Will CVS Stock Rise Post Q1?

Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data

  • After moving 4% or more over a five-day period, the stock rose in the next five days on 47% of the occasions.
  • After moving 7% or more over a ten-day period, the stock rose in the next ten days on 48% of the occasions
  • After moving 11% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 53% of the occasions.

CVS Health (CVS) Stock Return (Recent) Comparison With Peers

  • Five-Day Return: WBA highest at 6.1%; TGT lowest at -1.4%
  • Ten-Day Return: CVS highest at 7.0%; TGT lowest at -2.3%
  • Twenty-One Day Return: CVS highest at 11.2%; WBA lowest at 6.0%

 

[Updated: Nov 2, 2021] CVS Q3 Earnings Preview

CVS Health (NYSE: CVS) is scheduled to report its Q3 2021 results on Wednesday, Nov 3. We expect the company to likely post revenue and earnings marginally above the street expectations, driven by a recovery in its pharmacy management business. With the spread of the delta variant, the company likely saw some uptick in Covid-19 testing demand, as well. However, a slowdown in overall Covid-19 vaccination rate likely resulted in a decline in revenue contribution from Covid-19 vaccine administration. Also, a rebound in total procedure volume will likely result in higher benefit costs, weighing on the overall earnings growth, in our view. For perspective, benefit costs as a percentage of premiums stood at 83.3% in the first half of 2021, compared to 75.6% in the prior year period. Furthermore, our forecast indicates that CVS’ valuation is $96 per share, which is only 6% above the current market price of around $91, implying CVS stock has only a little room for growth. Our interactive dashboard analysis on CVS Health’s Pre-Earnings has additional details.

(1) Revenues expected to be marginally above the consensus estimates

Trefis estimates CVS Health’s Q3 2021 net revenues to be around $70.6 billion, slightly above the $70.5 billion consensus estimate. Revenue growth is expected to be led by the Covid-19 vaccination, which CVS is administering in over 8,000 locations. However, given the rise in overall vaccination rate, the demand for testing has come down. As such, CVS’ revenues from administering the Covid-19 testing is expected to see a sequential decline. On the Aetna side, the company will likely continue to add new Medicaid members. Also, given an increase in hospital visits, the company’s pharmacy business is likely to see steady growth in Q3.  Our dashboard on CVS Health’s Revenues offers more details on the company’s segments.

2) EPS also likely to be just above the consensus estimates

CVS Health’s Q3 2021 adjusted earnings per share (EPS) is expected to be $1.81 per Trefis analysis, compared to the consensus estimate of $1.78. CVS Health’s adjusted net income of $3.2 billion in Q2 2021 reflected a 7.6% drop from its $3.5 billion figure in the prior-year quarter. This can be attributed to contraction of margins, partly due to higher benefit costs. However, for the full-year 2021, we expect the adjusted EPS to be higher at $7.75, compared to $7.50 seen in 2020.

(3) Stock price estimate just above the current market price

Going by our CVS Health’s Valuation with an EPS estimate of $7.75 and a P/E multiple of 12x in 2021, this translates into a price of $96, which is 6% above the current market price of around $91. While the 12x figure compares with levels of 9x – 10x seen over the recent years, we believe the P/E multiple will likely increase with margin expansion and better earnings growth over the coming years, partly driven by an overall rebound in economic growth, as the Covid-19 crisis winds down.

Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year.

While CVS stock has a little room for growth, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Flir Systems vs. CVS Health.

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.

Invest with Trefis Market Beating Portfolios

See all Trefis Price Estimates